Literature DB >> 6218857

Influence of previous gold toxicity on subsequent development of penicillamine toxicity.

P J Smith, W R Swinburn, D R Swinson, I M Stewart.   

Abstract

The incidence of penicillamine toxicity was determined in 250 patients who had never previously received gold, 76 patients who had received gold without toxic reaction, and 79 patients with a previous history of gold toxicity. The results suggest that there may be a higher incidence of penicillamine toxicity in patients who have previously shown toxic reactions. The interval between stopping the gold and starting the penicillamine did not influence incidence of toxicity. The development of a rash during gold treatment does not seem to influence the development of a rash during penicillamine treatment, but patients who have had proteinuria or bone-marrow depression during gold treatment may have an increased likelihood of developing a similar side effect with penicillamine.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6218857      PMCID: PMC1499435          DOI: 10.1136/bmj.285.6342.595

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  4 in total

1.  Adverse reactions to D-penicillamine after gold toxicity.

Authors:  M J Dodd; I D Griffiths; M Thompson
Journal:  Br Med J       Date:  1980-06-21

2.  Does the order of second-line treatment in rheumatoid arthritis matter?

Authors:  M M Steven; J A Hunter; R M Murdoch; H A Capell
Journal:  Br Med J (Clin Res Ed)       Date:  1982-01-09

3.  Trial comparing D-penicillamine and gold in rheumatoid arthritis. Preliminary report.

Authors:  E C Huskisson; T J Gibson; H W Balme; H Berry; H C Burry; R Grahame; F D Hart; D R Henderson; J A Wojtulewski
Journal:  Ann Rheum Dis       Date:  1974-11       Impact factor: 19.103

4.  Is penicillamine therapy in rheumatoid arthritis influenced by previous treatment with gold?

Authors:  M Webley; E N Coomes
Journal:  Br Med J       Date:  1978-07-08
  4 in total
  6 in total

Review 1.  Drug toxicity.

Authors:  H A Bird
Journal:  Ann Rheum Dis       Date:  1990-05       Impact factor: 19.103

2.  HLA types in patients with rheumatoid arthritis developing leucopenia after both gold and sulphasalazine treatment.

Authors:  H Bliddal; B Eiberg; P Helin; A Svejgaard
Journal:  Ann Rheum Dis       Date:  1989-07       Impact factor: 19.103

3.  Penicillamine induced myasthenia reactivated by gold.

Authors:  A P Moore; A C Williams; P Hillenbrand
Journal:  Br Med J (Clin Res Ed)       Date:  1984-01-21

Review 4.  Clinical pharmacokinetics of D-penicillamine.

Authors:  P Netter; B Bannwarth; P Péré; A Nicolas
Journal:  Clin Pharmacokinet       Date:  1987-11       Impact factor: 6.447

Review 5.  Slow-acting antirheumatic drugs. Drug interactions of clinical significance.

Authors:  R A Munro; R D Sturrock
Journal:  Drug Saf       Date:  1995-07       Impact factor: 5.606

Review 6.  Clinically important drug interactions with disease-modifying antirheumatic drugs.

Authors:  C J Haagsma
Journal:  Drugs Aging       Date:  1998-10       Impact factor: 4.271

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.